Related Experiment Video

Updated: Aug 19, 2026

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

PPARs as drug targets to modulate inflammatory responses?

Raphaël Genolet1, Walter Wahli, Liliane Michalik

  • 1Center for Integrative Genomics, NCCR Frontiers in Genomics, University of Lausanne, CH-1015 Lausanne, Switzerland.

Current Drug Targets. Inflammation and Allergy
|December 9, 2004
PubMed

Insights

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that act as anti-inflammatory transcription factors. This review explores how PPARs regulate immune responses and their therapeutic potential for inflammatory diseases.

Area of Science:

  • Molecular Biology
  • Immunology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors.
  • PPARs (alpha, beta/delta, gamma) function as anti-inflammatory transcription factors.
  • PPARs modulate innate and adaptive immunity by interacting with transcription factors like NFkB, AP-1, and C/EBP.

Purpose of the Study:

  • To review the mechanisms by which PPARs regulate inflammatory responses.
  • To discuss the therapeutic applications of PPAR-specific ligands in treating inflammatory conditions.

Main Methods:

  • Literature review of studies on PPARs and inflammation.
  • Analysis of molecular pathways involving PPARs and immune cells (macrophages, B cells, T cells).

Main Results:

  • PPARs exert anti-inflammatory effects through negative interference with key inflammatory transcription factors.
  • PPARs directly influence the function of critical immune cells.
  • PPARs represent a potential therapeutic target for managing inflammation.

Conclusions:

  • PPARs are crucial regulators of inflammatory processes.
  • Targeting PPARs with specific ligands offers a promising strategy for treating inflammatory diseases like IBD, atherosclerosis, Parkinson's, and Alzheimer's.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...